Innovative and Articulate: New Zircon Phase III Data Presented at SNMMI – Potential Utility of TLX250 CDX in Staging and Monitoring CCRCC
Telix Pharmaceuticals Announces Positive Results from Phase III Study MELBOURNE, Australia, June 26, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). New Data…